<- Go Home
NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Market Cap
$3.9B
Volume
850.5K
Cash and Equivalents
$538.4M
EBITDA
-$202.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$35.2M
Profit Margin
100.00%
52 Week High
$42.00
52 Week Low
$14.06
Dividend
N/A
Price / Book Value
5.38
Price / Earnings
-17.75
Price / Tangible Book Value
5.39
Enterprise Value
$3.2B
Enterprise Value / EBITDA
-15.64
Operating Income
-$202.9M
Return on Equity
39.94%
Return on Assets
-20.70
Cash and Short Term Investments
$702.9M
Debt
$266.0K
Equity
$728.1M
Revenue
$35.2M
Unlevered FCF
-$69.1M
Sector
Biotechnology
Category
N/A